ClinicalTrials.gg
CompletedNCT05299359Updated Oct 21, 2024Results posted

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

A Phase 3 interventional study of TAK-019 in Coronavirus Disease (COVID-19), sponsored by Takeda. Completed at 2 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
16th of 18
150 · median 997
Started
2022
with 4 others
Phase 3
7 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
1 of 18
Takeda

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 16th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 7th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019 for participants who will receive TAK-019 as heterologous booster vaccination.

This study consists of two parts, main part and extension part. Firstly, participants who completed 2 doses primary vaccinations 6 to 12 months prior to the trial vaccination can take part in main study. At the first visit of main part of this study, the study doctor will check if each person can take part. Participants who can take part will receive an injection of TAK-019 as booster vaccination.

Participants will be asked to record their temperature and any medical problems in an electronic diary for up to 7 days after the injection. During the main part, participants will visit the clinic for regular check-ups, blood tests, and sometimes for nose swab samples. When all participants have attended a clinic visit 28 days after the injection, the study sponsor (Takeda) will check how many participants have made enough antibodies to protect them against Covid-19.

Participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will be able to decide to take part in the extension part of this study. At the first visit of extension part of this study, the study doctor will check if each person can take part. Participants who can take part will receive an injection of TAK-019 as a second booster vaccination at the first visit of extension part.

The participants will stay in the main part of this study for up to 12 months after they have had their injection or up to the start of extension part. For participants who will take part in the extension part, they will stay in the extension part for up to 12 months from the start of extension part. During this time, the doctors will continue to collect blood samples to check immune response. Also, they will check if participants have any more side effects from TAK-019.

03

Conditions studied

  • Coronavirus Disease (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

MAIN PART:

  1. Healthy Japanese male and female adult participants aged >= 20 years of age at the time of signing of .
  2. Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine which is available in Japan 6 to 12 months prior to the trial vaccination.

    EXTENSION PART:

  3. Participants who received the first trial vaccination at least 5 months earlier and are currently enrolled in the Main Part (ie, not have withdrawn or discontinued early).

Exclusion criteria

Exclusion Criteria:

MAIN PART:

  1. Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.
  2. Participant who received a booster vaccination (i.e. 3rd dose)
  3. Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.
  4. Participants who were tested positive for SARS-CoV-2 prior to the trial.
  5. Participants who have traveled outside of Japan in the 30 days prior to the trial participation.
  6. Participants with a active infection or oral temperature >= 38 degree Celsius within 3 days of the intended date of the first single booster vaccination.
  7. Participants with (BMI) greater than or equal to 30 kg/m\^2 (BMI= weight in kg/ height in meters\^2)

    EXTENSION PART:

  8. Participants with a clinically significant active infection or oral temperature >=38 degree Celsius within 3 days of the intended date of the second single booster vaccination.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    TAK-019 Main Part

    TAK-019 0.5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm

    Biological: TAK-019

  • Experimental
    TAK-019 Extension Part

    TAK-019 0 .5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm. The participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will receive a second single booster vaccination of TAK-019 by intramuscular injection.

    Biological: TAK-019

Interventions

  • BiologicalTAK-019

    TAK-019 intramuscular injection

06

What researchers measure

Primary outcomes

  1. Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 20. GMT for each group and GMT ratio of neutralizing antibody titers to the ancestral strain (wild-type virus) on Day15 after a single booster vaccination (14 days after the booster vaccination) compared with that observed on Day 36 (14 days after the second vaccination) in participants from the TAK-019-1501 study (NCT04712110) were reported. GMT ratio was calculated with GMT of TAK-019-3001 on Day 15 divided by GMT of TAK-019-1501 study on Day 36. Here, ELISA is Enzyme-linked immunosorbent assay.

    Time frame: Day 15 for this study (14 days after the vaccination); Day 36 for TAK-019-1501 study (14 days after the second vaccination)

  2. Main Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination

    AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.

    Time frame: Main Part: 7 days after the first single booster vaccination

  3. Main Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination

    Solicited systemic AEs were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting, and headache.

    Time frame: Main Part: 7 days after the first single booster vaccination

  4. Main Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination

    Unsolicited AEs defines as other AEs than solicited local AEs and solicited systemic AEs.

    Time frame: Main Part: 28 days after the first single booster vaccination

  5. Main Part: Percentage of Participants With Solicited and Unsolicited Serious Adverse Events (SAE) Until Day 29

    An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

    Time frame: Main Part: Up to Day 29

  6. Main Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 29

    An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the Potential Immune Mediated Medical Conditions (PIMMC) and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

    Time frame: Main Part: Up to Day 29

  7. Main Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 29

    MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

    Time frame: Main Part: Up to Day 29

  8. Main Part: Percentage of Participants With Any AE Leading to Withdrawal From the Trial Until Day 29

    Percentage of participants with any AE leading to withdrawal from the trial until Day 29 was reported.

    Time frame: Main Part: Up to Day 29

  9. Main Part: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 29

    Percentage of participants with SARS-CoV-2 infection until Day 29 of the main part of the trial were reported in this outcome measure.

    Time frame: Main Part: Up to Day 29

Secondary outcomes

  1. Main Part: GMT of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 8, 15, 29, 91, 181, and 366

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.

    Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366

  2. Main Part: Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366

    GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of trial vaccination.

    Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366

  3. Main Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366

    SCR was defined as percentage of participants with 4-fold or more rises from baseline in titer. Baseline was defined as the last measurement taken before the first dose of trial vaccination.

    Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366

  4. Main Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366

    The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50 percent (%) of the replicate wells were protected from infection (microneutralization \[MN\] with an inhibitory concentration of 50% \[MN50\]). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.

    Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366

  5. Main Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366

    The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of trial vaccination.

    Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366

  6. Main Part: SCR of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366

    The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in from baseline. Baseline was defined as the last measurement taken before the first dose of trial vaccination.

    Time frame: Main Part: Day 8, 15, 29, 91, 181, and 366

  7. Main Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Main Part of Trial

    An SAE was defined as any untoward medical occurrence that: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

    Time frame: Main Part: Up to Day 366

  8. Main Part: Percentage of Participants With AESI Throughout the Main Part of Trial

    An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

    Time frame: Main Part: Up to Day 366

  9. Main Part: Percentage of Participants With MAAEs Throughout the Main Part of Trial

    MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

    Time frame: Main Part: Up to Day 366

  10. Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Main Part of Trial

    Percentage of participants with any AE leading to participant's withdrawal from the trial from the day of the first single booster vaccination throughout the main part of trial was reported.

    Time frame: Main Part: Day 1 up to Day 366

  11. Main Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Main Part of Trial

    Percentage of participants with SARS-CoV-2 infection throughout the main part of trial was reported.

    Time frame: Main Part: Day 1 up to Day 366

  12. Extension Part: GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 15, 29, 91, 181, and 366

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.

    Time frame: Extension Part: Day 15, 29, 91, 181, and 366

  13. Extension Part: GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366

    The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.

    Time frame: Extension Part: Day 15, 29, 91, 181, and 366

  14. Extension Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366

    SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline. Where extension part baseline was defined as last measurement taken before the second booster vaccination.

    Time frame: Extension Part: Day 15, 29, 91, 181, and 366

  15. Extension Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366

    The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.

    Time frame: Extension Part: Day 15, 29, 91, 181, and 366

  16. Extension Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366

    The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.

    Time frame: Extension Part: Day 15, 29, 91, 181, and 366

  17. Extension Part: SCR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366

    The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline.

    Time frame: Extension Part: Day 15, 29, 91, 181, and 366

  18. Extension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part

    AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.

    Time frame: Extension Part: 7 days after the second single booster vaccination

  19. Extension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part

    Solicited systemic AEs included were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.

    Time frame: Extension Part: 7 days after the second single booster vaccination

  20. Extension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination in Extension Part

    Unsolicited AEs defined as AEs other than solicited local AEs and solicited systemic AEs.

    Time frame: Extension Part: 28 days after the second single booster vaccination

  21. Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Until Extension Part Day 29

    An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

    Time frame: Extension Part: Up to Day 29

  22. Extension Part: Percentage of Participants With AESIs Until Extension Part Day 29

    An AESI was defined as AEs that will be specifically highlighted to the investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

    Time frame: Extension Part: Up to Day 29

  23. Extension Part: Percentage of Participants With MAAEs Until Extension Part Day 29

    MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

    Time frame: Extension Part: Up to Day 29

  24. Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial Until Extension Part Day 29

    Percentage of participants with any AEs leading to withdrawal from the trial until extension part Day 29 was reported.

    Time frame: Extension Part: Up to Day 29

  25. Extension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 29

    Percentage of participants with SARS-CoV-2 infection until extension part Day 29 was reported.

    Time frame: Extension Part: Up to Day 29

  26. Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Extension Part of the Trial

    An SAE was defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

    Time frame: Extension Part: Up to Day 366

  27. Extension Part: Percentage of Participants With AESIs Throughout the Extension Part of the Trial

    An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

    Time frame: Extension Part: Up to Day 366

  28. Extension Part: Percentage of Participants With MAAEs Throughout the Extension Part of the Trial

    MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

    Time frame: Extension Part: Up to Day 366

  29. Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part of the Trial

    Percentage of participants with any AEs leading to withdrawal from the trial from the day of the second single booster vaccination throughout the extension part of the trial was reported.

    Time frame: Extension Part: From Day 1 up to Day 366

  30. Extension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part of Trial

    Percentage of participants with SARS-CoV-2 infection throughout the extension part of trial was reported.

    Time frame: Extension Part: Up to Day 366

07

Results

Posted Jul 28, 2023

Participant flow

Participants took part in the study at 2 investigative sites in Japan. Healthy Japanese participants who completed 2 doses of primary vaccinations 6 to 12 months prior to trial vaccination were enrolled to receive a first dose of single booster vaccination of TAK-019 in Main Part and a second dose of booster vaccination of TAK-019 in Extension Part.

Main Part: Day 1 up to Day 366
Participant flow — Main Part: Day 1 up to Day 366
MilestoneMain Part: TAK-019Extension Part: TAK-019
Started1500
Completed170
Not completed1330
Withdrew: Participants moved to extension part1290
Withdrew: Other20
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up10
Extension Part: Day 1 to Day 366
Participant flow — Extension Part: Day 1 to Day 366
MilestoneMain Part: TAK-019Extension Part: TAK-019
Started0129
Completed0121
Not completed08
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject05
Withdrew: Other01

Outcome measures

PrimaryMain Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 20. GMT for each group and GMT ratio of neutralizing antibody titers to the ancestral strain (wild-type virus) on Day15 after a single booster vaccination (14 days after the booster vaccination) compared with that observed on Day 36 (14 days after the second vaccination) in participants from the TAK-019-1501 study (NCT04712110) were reported. GMT ratio was calculated with GMT of TAK-019-3001 on Day 15 divided by GMT of TAK-019-1501 study on Day 36. Here, ELISA is Enzyme-linked immunosorbent assay.

Time frame:
Day 15 for this study (14 days after the vaccination); Day 36 for TAK-019-1501 study (14 days after the second vaccination)
Reported as:
Geometric mean · ELISA units per mL (EU/mL)
Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study
ELISA units per mL (EU/mL)Main Part: Day 15 of This Study: TAK-019Day 36 for TAK-019-1501 Study
Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study1143.9 (1000.5 to 1307.9)884.4 (749.0 to 1044.4)
Statistical analysis
  • Main Part: Day 15 of This Study: TAK-019 vs Day 36 for TAK-019-1501 Study · Ls mean difference: 1.18 · 95% CI 0.95 to 1.47
PrimaryMain Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination

AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.

Time frame:
Main Part: 7 days after the first single booster vaccination
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination
Percentage of ParticipantsMain Part: TAK-019
Main Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination74.0
PrimaryMain Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination

Solicited systemic AEs were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting, and headache.

Time frame:
Main Part: 7 days after the first single booster vaccination
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination
Percentage of ParticipantsMain Part: TAK-019
Main Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination48.0
PrimaryMain Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination

Unsolicited AEs defines as other AEs than solicited local AEs and solicited systemic AEs.

Time frame:
Main Part: 28 days after the first single booster vaccination
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination
Percentage of ParticipantsMain Part: TAK-019
Main Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination4.67
PrimaryMain Part: Percentage of Participants With Solicited and Unsolicited Serious Adverse Events (SAE) Until Day 29

An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

Time frame:
Main Part: Up to Day 29
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Solicited and Unsolicited Serious Adverse Events (SAE) Until Day 29
Percentage of ParticipantsMain Part: TAK-019
Solicited SAEs up to Day 290
Unsolicited SAEs up to Day 290
PrimaryMain Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 29

An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the Potential Immune Mediated Medical Conditions (PIMMC) and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

Time frame:
Main Part: Up to Day 29
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 29
Percentage of ParticipantsMain Part: TAK-019
Main Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 290
PrimaryMain Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 29

MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

Time frame:
Main Part: Up to Day 29
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 29
Percentage of ParticipantsMain Part: TAK-019
Main Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 290.7
PrimaryMain Part: Percentage of Participants With Any AE Leading to Withdrawal From the Trial Until Day 29

Percentage of participants with any AE leading to withdrawal from the trial until Day 29 was reported.

Time frame:
Main Part: Up to Day 29
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Any AE Leading to Withdrawal From the Trial Until Day 29
Percentage of ParticipantsMain Part: TAK-019
Main Part: Percentage of Participants With Any AE Leading to Withdrawal From the Trial Until Day 290
PrimaryMain Part: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 29

Percentage of participants with SARS-CoV-2 infection until Day 29 of the main part of the trial were reported in this outcome measure.

Time frame:
Main Part: Up to Day 29
Reported as:
Number · Percentage of Participants
Main Part: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 29
Percentage of ParticipantsMain Part: TAK-019
Main Part: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 290
SecondaryMain Part: GMT of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 8, 15, 29, 91, 181, and 366

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.

Time frame:
Main Part: Day 8, 15, 29, 91, 181, and 366
Reported as:
Geometric mean · EU/mL
Main Part: GMT of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 8, 15, 29, 91, 181, and 366
EU/mLMain Part: TAK-019
At Day 824705.9 (21894.6 to 27878.2)
At Day 1535202.2 (31508.4 to 39329.1)
At Day 2936138.3 (32143.8 to 40629.2)
At Day 9126420.8 (23137.2 to 30170.4)
At Day 18120246.3 (11976.5 to 34226.5)
At Day 36631369.4 (15135.7 to 65014.5)
SecondaryMain Part: Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366

GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of trial vaccination.

Time frame:
Main Part: Day 8, 15, 29, 91, 181, and 366
Reported as:
Geometric mean · fold rise
Main Part: Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366
fold riseMain Part: TAK-019
At Day 84.21 (3.69 to 4.81)
At Day 156.00 (5.17 to 6.97)
At Day 296.16 (5.23 to 7.27)
At Day 914.43 (3.67 to 5.36)
At Day 1812.96 (1.45 to 6.04)
At Day 3664.28 (1.33 to 13.77)
SecondaryMain Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366

SCR was defined as percentage of participants with 4-fold or more rises from baseline in titer. Baseline was defined as the last measurement taken before the first dose of trial vaccination.

Time frame:
Main Part: Day 8, 15, 29, 91, 181, and 366
Reported as:
Number · percentage of participants
Main Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366
percentage of participantsMain Part: TAK-019
At Day 853.4 (45.0 to 61.6)
At Day 1570.9 (62.9 to 78.1)
At Day 2970.3 (62.2 to 77.5)
At Day 9156.1 (47.5 to 64.5)
At Day 18140.0 (16.3 to 67.7)
At Day 36661.5 (31.6 to 86.1)
SecondaryMain Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366

The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50 percent (%) of the replicate wells were protected from infection (microneutralization \[MN\] with an inhibitory concentration of 50% \[MN50\]). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.

Time frame:
Main Part: Day 8, 15, 29, 91, 181, and 366
Reported as:
Geometric mean · 1 per dilution
Main Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366
1 per dilutionMain Part: TAK-019
At Day 8729.7 (634.5 to 839.2)
At Day 151143.9 (1000.5 to 1307.9)
At Day 29775.5 (693.8 to 866.8)
At Day 91656.2 (559.6 to 769.4)
At Day 181844.5 (410.0 to 1739.3)
At Day 3661424.0 (597.0 to 3396.9)
SecondaryMain Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366

The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of trial vaccination.

Time frame:
Main Part: Day 8, 15, 29, 91, 181, and 366
Reported as:
Geometric mean · fold rise
Main Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366
fold riseMain Part: TAK-019
At Day 85.32 (4.55 to 6.23)
At Day 158.34 (6.93 to 10.04)
At Day 295.66 (4.68 to 6.84)
At Day 914.72 (3.72 to 5.97)
At Day 1815.79 (2.43 to 13.80)
At Day 3669.90 (2.84 to 34.54)
SecondaryMain Part: SCR of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366

The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in from baseline. Baseline was defined as the last measurement taken before the first dose of trial vaccination.

Time frame:
Main Part: Day 8, 15, 29, 91, 181, and 366
Reported as:
Number · percentage of participants
Main Part: SCR of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366
percentage of participantsMain Part: TAK-019
At Day 877.7 (70.1 to 84.1)
At Day 1584.5 (77.6 to 89.9)
At Day 2975.7 (67.9 to 82.3)
At Day 9167.6 (59.2 to 75.3)
At Day 18166.7 (38.4 to 88.2)
At Day 36676.9 (46.2 to 95.0)
SecondaryMain Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Main Part of Trial

An SAE was defined as any untoward medical occurrence that: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

Time frame:
Main Part: Up to Day 366
Reported as:
Number · percentage of participants
Main Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Main Part of Trial
percentage of participantsMain Part: TAK-019
Solicited SAEs Throughout the Main Part of Trial0
Unsolicited SAEs Throughout the Main Part of Trial0
SecondaryMain Part: Percentage of Participants With AESI Throughout the Main Part of Trial

An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

Time frame:
Main Part: Up to Day 366
Reported as:
Number · percentage of participants
Main Part: Percentage of Participants With AESI Throughout the Main Part of Trial
percentage of participantsMain Part: TAK-019
Main Part: Percentage of Participants With AESI Throughout the Main Part of Trial0
SecondaryMain Part: Percentage of Participants With MAAEs Throughout the Main Part of Trial

MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

Time frame:
Main Part: Up to Day 366
Reported as:
Number · percentage of participants
Main Part: Percentage of Participants With MAAEs Throughout the Main Part of Trial
percentage of participantsMain Part: TAK-019
Main Part: Percentage of Participants With MAAEs Throughout the Main Part of Trial20.0
SecondaryMain Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Main Part of Trial

Percentage of participants with any AE leading to participant's withdrawal from the trial from the day of the first single booster vaccination throughout the main part of trial was reported.

Time frame:
Main Part: Day 1 up to Day 366
Reported as:
Number · percentage of participants
Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Main Part of Trial
percentage of participantsMain Part: TAK-019
Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Main Part of Trial0
SecondaryMain Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Main Part of Trial

Percentage of participants with SARS-CoV-2 infection throughout the main part of trial was reported.

Time frame:
Main Part: Day 1 up to Day 366
Reported as:
Number · percentage of participants
Main Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Main Part of Trial
percentage of participantsMain Part: TAK-019
Main Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Main Part of Trial14.0
SecondaryExtension Part: GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 15, 29, 91, 181, and 366

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.

Time frame:
Extension Part: Day 15, 29, 91, 181, and 366
Reported as:
Geometric mean · EU/mL
Extension Part: GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 15, 29, 91, 181, and 366
EU/mLExtension Part: TAK-019
At Day 15105057.6 (91624.1 to 120460.6)
At Day 2988154.1 (77487.0 to 100289.7)
At Day 9161090.0 (52488.3 to 71101.2)
At Day 18146199.1 (38752.6 to 55076.6)
At Day 36662823.7 (51897.3 to 76050.6)
SecondaryExtension Part: GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366

The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.

Time frame:
Extension Part: Day 15, 29, 91, 181, and 366
Reported as:
Geometric mean · fold rise
Extension Part: GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366
fold riseExtension Part: TAK-019
At Day 153.99 (3.47 to 4.59)
At Day 293.32 (2.91 to 3.78)
At Day 912.30 (1.96 to 2.70)
At Day 1811.72 (1.43 to 2.08)
At Day 3662.33 (1.84 to 2.95)
SecondaryExtension Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366

SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline. Where extension part baseline was defined as last measurement taken before the second booster vaccination.

Time frame:
Extension Part: Day 15, 29, 91, 181, and 366
Reported as:
Number · percentage of participants
Extension Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366
percentage of participantsExtension Part: TAK-019
At Day 1551.4 (41.7 to 61.0)
At Day 2940.9 (31.6 to 50.7)
At Day 9119.6 (12.6 to 28.4)
At Day 18116.7 (10.0 to 25.3)
At Day 36628.9 (19.8 to 39.4)
SecondaryExtension Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366

The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.

Time frame:
Extension Part: Day 15, 29, 91, 181, and 366
Reported as:
Geometric mean · 1 per dilution
Extension Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366
1 per dilutionExtension Part: TAK-019
At Day 151716.6 (1463.2 to 2013.9)
At Day 291732.1 (1465.8 to 2046.8)
At Day 911255.4 (1019.2 to 1546.3)
At Day 1811360.7 (1081.2 to 1712.6)
At Day 366660.0 (531.0 to 820.4)
SecondaryExtension Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366

The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.

Time frame:
Extension Part: Day 15, 29, 91, 181, and 366
Reported as:
Geometric mean · fold rise
Extension Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366
fold riseExtension Part: TAK-019
At Day 153.04 (2.59 to 3.57)
At Day 293.05 (2.57 to 3.63)
At Day 912.19 (1.81 to 2.66)
At Day 1812.34 (1.86 to 2.94)
At Day 3661.16 (0.86 to 1.55)
SecondaryExtension Part: SCR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366

The neutralization titer was expressed as the reciprocal of the highest dilution at \>= 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline.

Time frame:
Extension Part: Day 15, 29, 91, 181, and 366
Reported as:
Number · percentage of participants
Extension Part: SCR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366
percentage of participantsExtension Part: TAK-019
At Day 1551.4 (41.7 to 61.0)
At Day 2952.7 (43.0 to 62.3)
At Day 9130.8 (22.3 to 40.5)
At Day 18136.3 (27.0 to 46.4)
At Day 36624.4 (16.0 to 34.6)
SecondaryExtension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part

AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.

Time frame:
Extension Part: 7 days after the second single booster vaccination
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part73.6
SecondaryExtension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part

Solicited systemic AEs included were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.

Time frame:
Extension Part: 7 days after the second single booster vaccination
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part51.2
SecondaryExtension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination in Extension Part

Unsolicited AEs defined as AEs other than solicited local AEs and solicited systemic AEs.

Time frame:
Extension Part: 28 days after the second single booster vaccination
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination in Extension Part
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination in Extension Part7.0
SecondaryExtension Part: Percentage of Participants With Solicited and Unsolicited SAEs Until Extension Part Day 29

An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

Time frame:
Extension Part: Up to Day 29
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Until Extension Part Day 29
percentage of participantsExtension Part: TAK-019
Solicited SAEs Up to Extension Part Day 290
Unsolicited SAEs Up to Extension Part Day 290.8
SecondaryExtension Part: Percentage of Participants With AESIs Until Extension Part Day 29

An AESI was defined as AEs that will be specifically highlighted to the investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

Time frame:
Extension Part: Up to Day 29
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With AESIs Until Extension Part Day 29
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With AESIs Until Extension Part Day 290
SecondaryExtension Part: Percentage of Participants With MAAEs Until Extension Part Day 29

MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

Time frame:
Extension Part: Up to Day 29
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With MAAEs Until Extension Part Day 29
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With MAAEs Until Extension Part Day 295.4
SecondaryExtension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial Until Extension Part Day 29

Percentage of participants with any AEs leading to withdrawal from the trial until extension part Day 29 was reported.

Time frame:
Extension Part: Up to Day 29
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial Until Extension Part Day 29
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial Until Extension Part Day 290
SecondaryExtension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 29

Percentage of participants with SARS-CoV-2 infection until extension part Day 29 was reported.

Time frame:
Extension Part: Up to Day 29
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 29
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 290
SecondaryExtension Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Extension Part of the Trial

An SAE was defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event. Solicited SAEs and unsolicited SAEs were reported.

Time frame:
Extension Part: Up to Day 366
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Extension Part of the Trial
percentage of participantsExtension Part: TAK-019
Solicited SAEs Throughout the Extension Part0
Unsolicited SAEs Throughout the Extension Part3.1
SecondaryExtension Part: Percentage of Participants With AESIs Throughout the Extension Part of the Trial

An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.

Time frame:
Extension Part: Up to Day 366
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With AESIs Throughout the Extension Part of the Trial
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With AESIs Throughout the Extension Part of the Trial0
SecondaryExtension Part: Percentage of Participants With MAAEs Throughout the Extension Part of the Trial

MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

Time frame:
Extension Part: Up to Day 366
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With MAAEs Throughout the Extension Part of the Trial
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With MAAEs Throughout the Extension Part of the Trial31.0
SecondaryExtension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part of the Trial

Percentage of participants with any AEs leading to withdrawal from the trial from the day of the second single booster vaccination throughout the extension part of the trial was reported.

Time frame:
Extension Part: From Day 1 up to Day 366
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part of the Trial
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part of the Trial0
SecondaryExtension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part of Trial

Percentage of participants with SARS-CoV-2 infection throughout the extension part of trial was reported.

Time frame:
Extension Part: Up to Day 366
Reported as:
Number · percentage of participants
Extension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part of Trial
percentage of participantsExtension Part: TAK-019
Extension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part of Trial10.9

Adverse events

Collected over Main Part: Day 1 up to 366 and Extension Part: Day 1 up to Day 366 (Participants who participated in the Main Part and the Extension Part, total participation duration was approximately 17 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Part: TAK-0190/150 (0%)0/150 (0%)123/150 (82%)
Extension Part: TAK-0190/129 (0%)4/129 (3.1%)107/129 (82.9%)
Most frequent serious events
Most frequent serious events
EventMain Part: TAK-019Extension Part: TAK-019
Cerebral thrombosisNervous system disorders0/1501/129
IleusGastrointestinal disorders0/1501/129
OsteoarthritisMusculoskeletal and connective tissue disorders0/1501/129
Spinal compression fractureInjury, poisoning and procedural complications0/1501/129
Most frequent other events
Showing 10 of 11
Most frequent other events
EventMain Part: TAK-019Extension Part: TAK-019
TendernessGeneral disorders102/15089/129
Injection site painGeneral disorders80/15065/129
MalaiseGeneral disorders39/15044/129
HeadacheNervous system disorders37/15037/129
MyalgiaMusculoskeletal and connective tissue disorders29/15034/129
FatigueGeneral disorders28/15033/129
COVID-19Infections and infestations21/15014/129
ArthralgiaMusculoskeletal and connective tissue disorders11/15018/129
NauseaGastrointestinal disorders10/15011/129
SwellingGeneral disorders7/15011/129

Baseline characteristics

Main Part: The safety analysis set included all participants who received at least 1 dose of the trial vaccination.

Age, Continuous
Age, Continuous(Years)Main Part: TAK-019
Mean45.7 ± 13.00
Sex: Female, Male
Sex: Female, Male(Participants)Main Part: TAK-019
Female78
Male72
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Part: TAK-019
American Indian or Alaska Native0
Asian150
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Main Part: TAK-019
Japan150
Weight
Weight(Kilograms (kg))Main Part: TAK-019
Mean61.70 ± 11.497
Height
Height(Centimeter (cm))Main Part: TAK-019
Mean164.47 ± 9.408
BMI
BMI(Kilogram (kg)/meter (m)^2)Main Part: TAK-019
Mean22.68 ± 2.940
08

Study locations

2 sites
  • Sumida Hospital
    Sumida-ku, Tokyo, Japan
  • PS Clinic
    Fukuoka, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jun 2022, 1 month.

Results were first posted in Jul 2023, 1 year 1 month after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2022
First posted
Mar 29, 2022
StartActual
Apr 15, 2022
Primary completionActual
Jun 11, 2022
CompletionActual
Oct 18, 2023
Results first posted
Jul 28, 2023
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05299359
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 29, 2022
Start date
Apr 15, 2022
Primary completion
Jun 11, 2022
Completion
Oct 18, 2023
Results posted
Jul 28, 2023
Last update
Oct 21, 2024

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion